KIN News and Press, Kindred Biosciences Inc. From 10/28/20

Kindred Biosciences to Announce Third Quarter 2020 Financial Results Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Monday, November 9, 2020. PR Newswire SAN FRANCISCO, Oct. 28, 2020 SAN FRANCISCO , Oct. 28, ...

Vaxart (NASDAQ: VXRT) is gearing up for a potential roll-out of its experimental COVID-19 vaccine. The clinical-stage biotechnology company is expanding its partnership with Kindred Biosciences (NASDAQ: KIN) to manufacture its oral vaccine candidate for the novel coronav...

Vaxart (VXRT) and Centaur Biopharmaceutical Services, a subsidiary of Kindred Biosciences (KIN) have expanded their agreement under which Centaur will manufacture Vaxart's oral vaccine for COVID-19 and other vaccine candidates. Centaur is a full-service contract development and manufacturing ...

Centaur Biopharmaceutical Services Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates PR Newswire SAN FRANCISCO, Oct. 7, 2020 SAN FRANCISCO , Oct. 7, 2020 /PRNewswire/ -- Centaur Biopharmaceutical Services Inc...

Kindred Biosciences Announces Expansion of Manufacturing Agreement with Vaxart for COVID-19 and Other Vaccine Candidates PR Newswire SAN FRANCISCO, Oct. 7, 2020 SAN FRANCISCO , Oct. 7, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmac...

This article is part of a series that provides an ongoing analysis of the changes made to Ariel Investments’ 13F stock portfolio on a quarterly basis. It is based on Ariel Investments’ regulatory 13F Form filed on 08/14/2020. John Rogers’ 13F portfolio value increased ~1...

Kindred Biosciences (NASDAQ: KIN ) announces  positive results from a pivotal efficacy study, evaluating KIND-030, a monoclonal antibody targeting canine parvovirus infection (CPV). More news on: Kindred Biosciences, Inc., Healthcare stocks news, Read more ...

SAN FRANCISCO , Sept. 16, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030, a monoclonal antibody targeting cani...

SAN FRANCISCO , Sept. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15 , the Cantor Global Heal...

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. Registration details and the company schedule can be seen here: https://ld500.ldmicro.co...